Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.
Status:
Recruiting
Trial end date:
2023-08-24
Target enrollment:
Participant gender:
Summary
The study is designed as a multicenter, randomized, double-blind, parallel group,
placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in
complement 3 glomerulopathy.